At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 131 enrolled
Drug / intervention
anti-SARS-CoV-2 convalescent plasmabiological
Likely dose
anti-SARS-CoV-2 convalescent plasma 2 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
In Brief
A Phase 2 clinical trial evaluating anti-SARS-CoV-2 convalescent plasma for COVID-19. Completed, enrolled 131 participants across 1 site.
Detailed Summary
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsFroedtert Hospital
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedApr 21, 2020
Enrollment StartMay 11, 2020
Primary CompletionFeb 10, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.2 years ago
Interventions
anti-SARS-CoV-2 convalescent plasmabiological
* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW ) * Study drug will be administered as a single intravenous infusion